Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My firm uses their technology - we utilize Comprehensive Cable and they use the Spectra7 microchip
at InfoComm '17 this year in Orlando and i even stopped by Comprehensives Booth and they mentioned the chip set....they were very excited that i heard of Spectra7 and i was very excited to see the $SPVNF chip set being used
RECORD QUARTER JUST HAD BY SPECTRA 7 Microsystes $SPVNF
Tesla Global Q2 Deliveries Increase 53% Y/Y
https://seekingalpha.com/article/4086409-tesla-global-q2-deliveries-increase-53-percent-y-y
Tesla (NASDAQ:TSLA) bears may not wish to take note of the simple fact stated in today's headline, but it remains a remarkable achievement nonetheless. Were Tesla any other technology company, a 53% y/y unit shipment increase of its main product would be cause for celebration.
But this is Tesla, and all those shorting the stock can taste blood in the water. This is starting to look like the big kill they've been waiting for. They may be right, but for all its problems, Tesla is one company I would never short, for the simple reason that I want it to succeed.
And it still may. Although the bears like to portray Tesla's fate as no longer in doubt, it is very much. Tesla has enormous technical obstacles to overcome, but its CEO, Elon Musk, has proved adept at overcoming enormous obstacles. SpaceX is proof of that.
Tesla's global deliveries also offer evidence that the conclusion is far from final. Tesla stated that problems with producing the 100 kWh battery packs caused the shortfall in deliveries. Bears may ridicule this explanation, but this amounts to second guessing of technical issues, which has never adequately served the bears' purposes. I find the explanation perfectly reasonable and refreshingly candid. Most of the mainstream automakers never admit to technical problems until forced to do so by government regulatory agencies.
If we accept that this really was a production problem, does this bode ill for Model 3? Not really, unless you accept the wildly optimistic projections of Musk in his latest Tweet storm. I certainly don't expect Tesla to achieve a run rate of 5,000 vehicles/week by the end of the year. Model 3 was always going to be a longer and more difficult production ramp than Tesla avowed.
$TSLA
Tesla wins giant battery contract in Australia, has 100-day deadline
https://www.reuters.com/article/us-australia-power-tesla-idUSKBN19S0EV
$TSLA
ARNA Stock Extends Hot Streak, Stays Nasdaq Darling
Arena Pharmaceuticals stock is one of the best on the Nasdaq today, up 9.7% to trade at $19.73, and just off a new annual high of $19.90, after JMP raised its rating on the stock to "market outperform" from "market perform." The biotech stock is now up 39% year-to-date, and has skyrocketed about 75% since hitting a record low of $11.30 on May 18.
A short squeeze could add fuel to ARNA stock's fire. Short interest represents more than 26% of the equity's total available float, and would take nearly a week to buy back, at Arena Pharmaceuticals' average daily trading volume.
http://www.schaeffersresearch.com/content/news/2017/07/07/amd-stock-rallies-general-electric-hits-another-new-low
$ARNA
$34 Price Targets, this appears to be just the beginning.
$ARNA
Sears closing more stores - $JCP to gain their market share
Sears to close 43 more stores
http://money.cnn.com/2017/07/07/news/companies/sears-stores-closing/index.html?iid=hp-stack-dom
Tesla is rallying after announcing plans for the world's largest battery farm $TSLA
http://markets.businessinsider.com/news/stocks/tesla-stock-price-breaks-losing-streak-after-largest-battery-farm-in-the-world-2017-7-1002156425
Arena Pharmaceutical $ARNA 19.25 UP 1.26 +7.00%
Volume: 1,704,754 @ 4:32:32 PM ET
Bid Ask Day's Range
19.1 19.25 18.74 - 19.9
http://investorshub.advfn.com/Arena-Pharmaceuticals-Inc-ARNA-8794/
Time to Buy Arena Pharmaceuticals, Inc. (ARNA) After Today’s Significant Increase?
https://finnewsdaily.com/time-to-buy-arena-pharmaceuticals-inc-arna-after-todays-significant-increase/
JMP Securities Upgrades Arena price target of $27.00. $ARNA
https://www.streetinsider.com/Analyst+Comments/JMP+Securities+Upgrades+Arena+Pharma+%28ARNA%29+to+Market+Outperform/13078400.html
SeekingAlpha: Tesla building world's largest battery system
Tesla (NASDAQ:TSLA) has agreed to build the world's largest lithium-ion battery storage project in South Australia as the state battles outages that have driven up energy prices.
The company outbid 91 other firms for the contract to install a 100 megawatt facility, while Elon Musk said that if the project is not completed in 100 days, it will be free.
TSLA +2.5% premarket
UPDATE 1-Tesla Q3 deliveries to include 3,500 vehicles in transit $TSLA
http://markets.businessinsider.com/news/stocks/r-update-1-tesla-q3-deliveries-to-include-3500-vehicles-in-transit-2017-7-1002157067
July 7 (Reuters) - Tesla Inc said current-quarter deliveries would include about 3,500 vehicles that were in transit to customers at the end of the second quarter, on a day the electric-car maker's first Model 3 rolls off the assembly line.
The company said on Monday it delivered about 47,100 electric sedans and SUVs in the first half of 2017, at the lower end of its own forecasts, putting pressure on the company's shares.
Tesla had then not provided details on the number of vehicles in transit.
The company, which blamed "severe shortfall" of new battery packs that constrained vehicle manufacturing until June, reiterated on Friday that combined deliveries of Model S and Model X in the second half of 2017 will likely exceed deliveries in the first half.
Registrations of Tesla vehicles in California fell 24 percent in April from a year earlier, according to data from industry consultant IHS Markit.
The numbers come as investors worry that demand for Tesla's luxury Model S sedan is waning ahead of the mass market Model 3 launch.
Tesla's shares, which spiked after the transit number announcement, gave up their gains to trade up 1.2 percent at $312.51. Separately, the company said it had won an Australian contract to install the world's biggest grid-scale battery.
(Reporting by Rishika Sadam in Bengaluru; Editing by Sriraj Kalluvila)
Tesla Inc $TSLA Stock Will Hit $400 as Model 3 Hype Turns Reality
http://investorplace.com/2017/07/tesla-inc-tsla-stock-will-hit-400-as-model-3-hype-turns-reality/#.WV_unYTyvDc
Australian state picks Tesla to provide grid-scale battery $TSLA
http://markets.businessinsider.com/news/stocks/r-australian-state-picks-tesla-to-provide-grid-scale-battery-2017-7-1002154441
Price targets of $23 to $34 PPS there is so much upside to this.....
i start to think the R/S was timed with whatever positiveness is brewing up so that the stock could move hard........lord knows what sort of attention this would have drawn if it was moving at 5% clips in the dollar range lol
Arena Pharmaceutical $ARNA 17.99 UP 0.47 +2.68%
Volume: 1,043,660 @ 7:15:38 PM ET
“Speculative Buy” Rating Reiterated at Canaccord Genuity
https://sportsperspectives.com/2017/07/05/spectra7-microsystems-tsesev-speculative-buy-rating-reiterated-at-canaccord-genuity.html
Canaccord Genuity restated their speculative buy rating on shares of Spectra7 Microsystems Inc (TSE:SEV) in a research report report published on Thursday. The brokerage currently has a C$0.75 price objective on the stock.
Spectra7 Microsystems (TSE:SEV) opened at 0.37 on Thursday. The company’s 50-day moving average is $0.42 and its 200 day moving average is $0.42. The company’s market capitalization is $54.55 million. Spectra7 Microsystems has a 52 week low of $0.28 and a 52 week high of $0.57.
$SPVNF
Arena Pharmaceutical $ARNA 17.99 UP 0.47 +2.68%
Volume: 1,043,485 @ 4:40:32 PM ET
Spectra7 "..Record Revenue..." $SPVNF
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=132720054
Spectra7 Announces Preliminary Record Second Quarter 2017 Revenues
Spectra7 Reports Record Revenues(1), Higher Gross Margins(2), and Growing Acceptance of its Data Center Solutions
SAN JOSE, CA--(Marketwired - July 05, 2017) - (TSX: SEV) Spectra7 Microsystems Inc, ("Spectra7" or the "Company"), a leading provider of high-performance analog semiconductor products for broadband connectivity markets today announced preliminary selected unaudited financial results for the three month period ended June 30, 2017. Unless otherwise indicated, all dollar amounts in this press release are expressed in US dollars.
PRELIMINARY Q2 2017 RESULTS
The Company expects to report revenues of approximately $3.1 million1 for the second quarter of 2017, representing an increase of approximately 15% from the prior quarter and 19% from the same quarter in 2016. Second quarter growth was driven by broad-based adoption of the Company's patented active copper cable ("ACC") technology. Gross margin2 as a percentage of revenue is expected to be approximately 62%-64%, up from 60% in the previous quarter, driven by an improved product mix. Operating expenses for the Company, excluding non-cash items, are expected to be lower by approximately $100,000 from the prior quarter operating expenses which the Company expects to continue through 2017. As a result of the higher revenues, increased gross margin rate, and lower operating expenses, the Company's operating losses are expected to have decreased by over 26% sequentially quarter over quarter.
CEO COMMENTARY
"Our record revenue1 in the second quarter was driven by continued execution across our targeted markets," said Spectra7 CEO Raouf Halim. "We are also very pleased with the expected increase to our gross margin and reduction of our operating expenditures sequentially, further improving the profitability of the Company. Initial trials of GaugeChangerPlus™, Spectra7's ACC data center solution, have completed successfully at two Tier-one customers. Growing traction with key data center customers, leadership in the augmented, virtual and mixed reality markets, plus the closing of our recent financing put the Company in a strong position to continue our execution."
OTHER QUARTERLY HIGHLIGHTS
The Company successfully completed the first round technical evaluation of its GaugeChangerPlus™ solution by two Tier-one data center customers and continued strong market traction.
The Company secured two additional industry-leading mixed reality (MR) design wins in Q2.
Significant Tier-one MR design wins secured in Q1 are moving forward with material revenue growth expected in the second half of 2017.
On June 27, 2017, the Company closed a bought deal offering of units for aggregate gross proceeds of CAD$4,600,000 and the first tranche of a private placement of units for additional gross proceeds of CAD$1,312,300.
Amendments to the senior secured term loan facility with MidCap Financial (the "Loan Facility") became effective on June 27, 2017, which amendments, among other things, (i) extend the commencement date for principal payments under the Loan Facility from June 1, 2017 to June 1, 2018, and (ii) provide the Company to extend the maturity date of the Loan Facility by one year upon satisfaction of certain conditions precedent.
Unaudited financial statements for the Company's second quarter ended June 30, 2017 are expected to be released in August 2017. The Company looks forward to providing further updates on its progress this year.
MSG Board
http://investorshub.advfn.com/Spectra-7-SPVNF-30668/
CEO States "record revenue" $SPVNF
Gross margin2 as a percentage of revenue is expected to be approximately 62%-64%, up from 60% in the previous quarter, driven by an improved product mix
$SPVNF
Revenue up 15% from the prior quarter and 19% from the same quarter in 2016 - modest and steady - excellent
$SPVNF
Analysts: $ARNA 12-month price target $35.50 PPS
http://postanalyst.com/2017/07/03/an-inside-look-at-trading-hot-stocks-avid-technology-inc-avid-arena-pharmaceuticals-inc-arna/
Arena Pharmaceuticals, Inc. (ARNA) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.43 to 2.25 during a month. Analysts set a 12-month price target of $35.5 a share. The target implies a 110.43% spike from where the shares are currently trading. Also, the current price highlights a discount of 196.38% to analysts’ high consensus price target.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Intraday Trading
The counter witnessed a trading volume of 0.75 million shares versus an average volume of 0.35 million shares during last trading session. Its last month’s stock price volatility remained 7.44% which for the week approaches 7.22%. The lowest price the stock reached in the last trading day was $15.97 and compares with the $11.3 52-week low. The stock recovered 49.29% since its low point and has performed 18.8% year-to-date.
"...Thomson Reuters’ First Call...price target listed as $33.00"
Thomson Reuters’ First Call, which many consider to be the benchmark for EPS and consensus data, currently have the price target listed as $33.00. This is the consensus of all analyst targets from the brokerage firms polled by First Call
http://rockvilleregister.com/stock-update-on-arena-pharmaceuticals-inc-nasdaqarna/162130/
Analysts set a 12-month price target of $35.5 a share
http://postanalyst.com/2017/07/03/an-inside-look-at-trading-hot-stocks-avid-technology-inc-avid-arena-pharmaceuticals-inc-arna/
Arena Pharmaceuticals, Inc. (ARNA) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 2.43 to 2.25 during a month. Analysts set a 12-month price target of $35.5 a share. The target implies a 110.43% spike from where the shares are currently trading. Also, the current price highlights a discount of 196.38% to analysts’ high consensus price target.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Intraday Trading
The counter witnessed a trading volume of 0.75 million shares versus an average volume of 0.35 million shares during last trading session. Its last month’s stock price volatility remained 7.44% which for the week approaches 7.22%. The lowest price the stock reached in the last trading day was $15.97 and compares with the $11.3 52-week low. The stock recovered 49.29% since its low point and has performed 18.8% year-to-date.
Citigroup initiated coverage on $ARNA with a Buy rating. The price target for Arena Pharmaceuticals is set to $23.
https://www.benzinga.com/analyst-ratings/upgrades/17/06/9658081/benzingas-top-upgrades-downgrades-for-june-27-2017
Average "Buy" Rating @ $37.80 Consensus PPS
$ARNA
https://sportsperspectives.com/2017/07/05/somewhat-negative-news-coverage-very-likely-to-impact-arena-pharmaceuticals-arna-share-price-updated.html
Leerink Swann began coverage on $ARNA in a report on Friday, May 19th. They issued an “outperform” rating and a $50.00 price target on the stock
https://sportsperspectives.com/2017/07/05/somewhat-negative-news-coverage-very-likely-to-impact-arena-pharmaceuticals-arna-share-price-updated.html
$ANRAN
ValuEngine raised $ARNA from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st
https://sportsperspectives.com/2017/07/05/somewhat-negative-news-coverage-very-likely-to-impact-arena-pharmaceuticals-arna-share-price-updated.html
Zacks Investment Research raised $ARNA from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a research note on Tuesday
https://sportsperspectives.com/2017/07/05/somewhat-negative-news-coverage-very-likely-to-impact-arena-pharmaceuticals-arna-share-price-updated.html
Analysts have placed a $33 price target on Arena Pharmaceuticals
http://www.postanalyst.com/2017/07/05/hot-stocks-among-investors-arena-pharmaceuticals-inc-arna-vericel-corporation-vcel/
HOT STOCKS AMONG INVESTORS: ARENA PHARMACEUTICALS, INC. $ARNA
Analysts have placed a $33 price target on Arena Pharmaceuticals
http://www.postanalyst.com/2017/07/05/hot-stocks-among-investors-arena-pharmaceuticals-inc-arna-vericel-corporation-vcel/
I jumped back in - with analyst calling for $23 PPS - this has lots of room to move
$ARNA
Swquak on the Street Guest (Stating opinion) "Sears could Go To Bankruptcy Sometime In August"
$JCP looking to emerge as one of the few left standing to absorb market share
Bankrate, Inc. $RATE 14.075 UP 1.225 +9.53%
Volume: 310,411 @ 9:31:33 AM ET
Check out their facebook page - be sure to stop , like and leave a positive review
https://www.facebook.com/pg/spectra7microsystems/photos/?ref=page_internal
Spectra 7
$SPVNF